Background: The aim of the present was to determine bone mineral density (BMD) in type 1 diabetic children and the roles of hemoglobin A(1c), disease duration and pubertal stage on BMD changes.
Methods: Fifty-eight patients were investigated: 16 had been newly diagnosed (Diabetes(New)) and 42 were already on follow up (Diabetes(Follow up)). BMD of the lumbar vertebrae, HbA1c(HbA1c(last)), Ca, P, Mg were measured. Mean HbA1c of the previous year (HbA1c(1year)), the whole duration of diabetes (HbA1c(whole)), and diabetic impact index (HbA1c(whole) x diabetes duration) were calculated in the Diabetes(Follow up) group.
Results: Mean BMD-Z score (-0.61 +/- 0.99 g/cm(2)) of the whole group was significantly lower than zero. Osteopenia was present in 14 (24.1%), and osteoporosis in three (5.2%). HbA1c(whole) was the most important determinant effecting BMD-Z (r = -0.35, P < 0.05) with the cut-off for osteopenia and osteoporosis being 9.8% and 12.1%, respectively. The cut-off of diabetes duration for osteopenia was 3.6 years and it was more predictive for osteopenia compared to HbA1c(whole). In the Diabetes(New) group, the BMD-Z score of the early pubertal group was significantly lower than those in other pubertal groups.
Conclusion: BMD is affected in diabetic children, and HbA1c(whole) and diabetes duration are the most important determinants. Pubertal stage is another determinant of BMD, especially in newly diagnosed patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1442-200X.2007.02451.x | DOI Listing |
J Pediatr Endocrinol Metab
January 2025
Division of Gastroenterology, Hepatology, & Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Objectives: The association of celiac disease (CD) in type 1 diabetes mellitus (T1DM) is well-established, yet variation exists in screening practices. This study measures the accuracy of early screening with tissue transglutaminase Immunoglobulin A (TTG-IgA) and endomysial antibody (EMA) in newly diagnosed T1DM.
Methods: This is a retrospective study of children with T1DM between 2013 and 2019 with early CD screening and follow-up.
Nat Methods
January 2025
Statistical Center for Single-Cell and Spatial Genomics, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Spatial molecular profiling has provided biomedical researchers valuable opportunities to better understand the relationship between cellular localization and tissue function. Effectively modeling multimodal spatial omics data is crucial for understanding tissue complexity and underlying biology. Furthermore, improvements in spatial resolution have led to the advent of technologies that can generate spatial molecular data with subcellular resolution, requiring the development of computationally efficient methods that can handle the resulting large-scale datasets.
View Article and Find Full Text PDFCurr Obes Rep
January 2025
Section of Nutrition, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Purpose Of Review: To review evidence supporting human umbilical cord mesenchymal stem cells (UC-MSC) as an innovative model system advancing obesity precision medicine.
Recent Findings: Obesity prevalence is increasing rapidly and exposures during fetal development can impact individual susceptibility to obesity. UC-MSCs exhibit heterogeneous phenotypes associated with maternal exposures and predictive of child cardiometabolic outcomes.
Nat Rev Nephrol
January 2025
APHP, Reference Center for Rare Diseases of Calcium and Phosphate Metabolism, and Filière OSCAR, endo ERN and ERN BOND, Paris, France.
X-linked hypophosphataemia (XLH) is a rare metabolic bone disorder caused by pathogenic variants in the PHEX gene, which is predominantly expressed in osteoblasts, osteocytes and odontoblasts. XLH is characterized by increased synthesis of the bone-derived phosphaturic hormone fibroblast growth factor 23 (FGF23), which results in renal phosphate wasting with consecutive hypophosphataemia, rickets, osteomalacia, disproportionate short stature, oral manifestations, pseudofractures, craniosynostosis, enthesopathies and osteoarthritis. Patients with XLH should be provided with multidisciplinary care organized by a metabolic bone expert.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!